MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes)

MELAS Syndrome

Introduction

Melas Syndrome (mitochondrial Encephalomyopathy, lactic acidosis (see insulin-resistance-ad), And stroke Like Episodes) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

MELAS (mitochondrial Encephalomyopathy, lactic acidosis (see insulin-resistance-ad), and stroke-like episodes (see stroke is a rare, maternally inherited mitochondrial disorder that predominantly affects the nervous system and muscles. First described by Pavlakis et al. in 1984, MELAS is one of the most common and well-characterized mitochondrial diseases, with an estimated incidence of approximately 1 in 4,000 live births . The condition is caused by point mutations in mitochondrial DNA (mtDNA (see mitochondrial-dynamics)), most commonly the m.3243A>G mutation in the MT-TL1 (mitochondrial tRNA^Leu) gene encoding mitochondrial tRNA^Leu(UUR)^, which is present in approximately 80% of affected individuals . [@melas]

MELAS belongs to the broader group of mitochondrial diseases and shares features with other mitochondrial syndromes. The hallmark of the disease is the occurrence of stroke-like episodes (see stroke (SLEs) that typically begin between ages 2 and 40, leading to progressive neurological disability. Unlike ischemic strokes, these episodes do not conform to vascular territories and are thought to result from mitochondrial angiopathy and impaired energy metabolism in the brain . [@biomarking]

...

MELAS Syndrome

Introduction

Melas Syndrome (mitochondrial Encephalomyopathy, lactic acidosis (see insulin-resistance-ad), And stroke Like Episodes) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

MELAS (mitochondrial Encephalomyopathy, lactic acidosis (see insulin-resistance-ad), and stroke-like episodes (see stroke is a rare, maternally inherited mitochondrial disorder that predominantly affects the nervous system and muscles. First described by Pavlakis et al. in 1984, MELAS is one of the most common and well-characterized mitochondrial diseases, with an estimated incidence of approximately 1 in 4,000 live births . The condition is caused by point mutations in mitochondrial DNA (mtDNA (see mitochondrial-dynamics)), most commonly the m.3243A>G mutation in the MT-TL1 (mitochondrial tRNA^Leu) gene encoding mitochondrial tRNA^Leu(UUR)^, which is present in approximately 80% of affected individuals . [@melas]

MELAS belongs to the broader group of mitochondrial diseases and shares features with other mitochondrial syndromes. The hallmark of the disease is the occurrence of stroke-like episodes (see stroke (SLEs) that typically begin between ages 2 and 40, leading to progressive neurological disability. Unlike ischemic strokes, these episodes do not conform to vascular territories and are thought to result from mitochondrial angiopathy and impaired energy metabolism in the brain . [@biomarking]

Population prevalence studies have estimated the carrier frequency of the m.3243A>G mutation to be remarkably high — approximately 1 in 400 in some populations — though only a fraction of carriers develop the full MELAS phenotype. In Northern England, the prevalence of this variant in the adult population has been determined to be approximately 1 per 13,000 . [@eeg]

Genetics and Molecular Basis

mitochondrial DNA Mutations

MELAS is caused by pathogenic variants in mitochondrial DNA (mtDNA (see mitochondrial-dynamics)), which is maternally inherited. The mitochondrial genome is a 16,569-base pair circular molecule encoding 13 proteins of the respiratory chain, 22 tRNAs, and 2 rRNAs. [@novel]

• m.3243A>G (MT-TL1 (mitochondrial tRNA^Leu)): The most common causative mutation, accounting for approximately 80% of MELAS cases. This A-to-G transition at nucleotide position 3243 affects the mitochondrial tRNA^Leu(UUR)^ gene, impairing mitochondrial protein synthesis and mitochondrial-dysfunction-ad .
• m.3271T>C (MT-TL1 (mitochondrial tRNA^Leu)): The second most common mutation, responsible for approximately 10% of cases. This T-to-C substitution also affects the tRNA^Leu(UUR)^ gene .
• Other mutations: Additional pathogenic variants have been identified in MT-TL1 (mitochondrial tRNA^Leu) (m.3252A>G), MT-ND5 (NADH dehydrogenase subunit 5) (m.13513G>A, m.13514A>G), MT-ND1, MT-ND3, MT-ND4, and MT-TF genes, though these are less frequent .

Heteroplasmy and Threshold Effect

A critical concept in MELAS pathogenesis is heteroplasmy — the coexistence of mutant and wild-type mtDNA (see mitochondrial-dynamics) molecules within the same cell. Since each cell contains hundreds to thousands of mitochondria, each with multiple copies of mtDNA (see mitochondrial-dynamics), the proportion of mutant mtDNA (see mitochondrial-dynamics) varies between tissues and individuals . [^6]

• The threshold effect dictates that clinical manifestations appear only when the proportion of mutant mtDNA (see mitochondrial-dynamics) exceeds a tissue-specific threshold, typically 60–90% for the m.3243A>G mutation.
• Mitotic segregation during cell division can alter the proportion of mutant mtDNA (see mitochondrial-dynamics) in daughter cells, contributing to phenotypic variability even within families.
• Higher mutant loads in muscle and brain tissue correlate with more severe neurological and myopathic symptoms.

Maternal Inheritance

MELAS follows a maternal (mitochondrial) inheritance pattern. Children can only inherit mtDNA (see mitochondrial-dynamics) mutations from their mother, as sperm mitochondria are eliminated after fertilization. However, due to the mitochondrial bottleneck during oogenesis, the proportion of mutant mtDNA (see mitochondrial-dynamics) transmitted to offspring can vary dramatically, making genetic counseling challenging . [^7]

Pathophysiology

The pathogenesis of MELAS involves multiple interacting mechanisms that collectively explain the diverse clinical manifestations: [^8]

Impaired mitochondrial Energy Production

The primary defect in MELAS is impaired mitochondrial protein synthesis resulting from dysfunctional tRNA^Leu(UUR)^. This leads to: [^9]

• Reduced assembly and function of respiratory chain complexes, particularly Complex I (see mitochondrial-dysfunction-ad) (NADH:ubiquinone oxidoreductase) and Complex IV (see mitochondrial-dysfunction-ad) (cytochrome c oxidase) .
• Deficient mitochondrial-dysfunction-ad and decreased ATP production.
• Compensatory shift toward anaerobic glycolysis, resulting in elevated lactate levels (lactic acidosis (see insulin-resistance-ad)).
• Proliferation of abnormal mitochondria in affected tissues, visible as ragged-red fibers on muscle biopsy.

mitochondrial Angiopathy

A distinctive feature of MELAS pathophysiology is the involvement of small blood vessels: [^10]

• mitochondrial proliferation occurs in the smooth muscle and endothelial cells of cerebral arterioles and capillaries .
• This angiopathy leads to impaired vasodilation and blood perfusion, contributing to stroke-like episodes (see stroke.
• Affected vessels show strongly SDH-reactive (succinate dehydrogenase) walls on histochemistry.

Nitric Oxide Deficiency

Nitric oxide (NO) plays a crucial role in MELAS pathophysiology:

• Impaired Complex I (see mitochondrial-dysfunction-ad) function leads to decreased NADH oxidation and increased NADH/NAD+ ratio.
• Elevated lactate consumes NO through chemical reactions, while arginine (the NO precursor) becomes depleted.
• NO deficiency impairs vasodilation, exacerbating ischemia during stroke-like episodes (see stroke.
• This mechanism provides the rationale for L-arginine supplementation therapy .

oxidative-stress

Dysfunctional respiratory chain complexes generate excess oxidative-stress (oxidative-stress, leading to:

• Oxidative damage to mtDNA (see mitochondrial-dynamics), further impairing mitochondrial function in a vicious cycle.
• Damage to cellular membranes, proteins, and nuclear DNA.
• Activation of [apoptosis](/mechanisms/apoptosis) and [apoptosis](/mechanisms/apoptosis).

Clinical Features

MELAS is a multisystem disorder with highly variable clinical presentation. Symptoms typically appear in childhood or early adulthood after a period of normal early development.

Core Features

• Stroke-like episodes (SLEs): The hallmark of MELAS, typically occurring before age 40. [Episodes present with acute focal neurological deficits including hemiparesis, hemianopia, or cortical blindness. Unlike ischemic strokes, SLEs do not follow vascular territories and preferentially affect the parietal and occipital lobes].
• lactic acidosis (see insulin-resistance-ad): Elevated blood and cerebrospinal fluid lactate levels, reflecting impaired oxidative metabolism.
• Encephalopathy: Recurrent epilepsy, cognitive decline, and progressive dementia.
• Myopathy: Proximal muscle weakness, exercise intolerance, and easy fatigability.

Neurological Manifestations

• epilepsy: Focal or generalized epilepsy occur in approximately 70–90% of patients, often associated with stroke-like episodes (see stroke .
• Migraine-like headaches: Severe, recurrent headaches with visual aura.
• Cerebellar ataxia: Progressive difficulty with coordination and balance.
• Cognitive impairment: Progressive decline in executive function, memory, and language.
• Peripheral neuropathy: Sensorimotor neuropathy affecting the extremities.

Systemic Manifestations

• Sensorineural hearing loss: Present in 50–75% of patients.
• diabetes: Occurs in approximately 20–30% of patients with m.3243A>G.
• Short stature: Growth retardation is common, particularly with childhood onset.
• Cardiac involvement: Cardiomyopathy (hypertrophic or dilated), Wolff-[Parkinson](/diseases/parkinsons-disease)-White syndrome, and conduction defects.
• Ophthalmological findings: Pigmentary retinopathy, optic atrophy, and external ophthalmoplegia.
• Gastrointestinal dysfunction: Nausea, vomiting, intestinal pseudo-obstruction.
• Renal tubular dysfunction: Proximal tubular acidosis, focal segmental glomerulosclerosis.

Diagnosis

Clinical Diagnostic Criteria

The Hirano criteria (1992) and subsequent modifications require:

stroke-like episodes (see stroke before age 40.

Encephalopathy with epilepsy, dementia, or both.

mitochondrial myopathy with lactic acidosis (see insulin-resistance-ad), ragged-red fibers, or both.

At least two of: normal early development, recurrent headache, recurrent vomiting.

Laboratory Findings

• Elevated serum/CSF lactate: A hallmark finding, though not always present at rest.
• Elevated serum/CSF lactate-to-pyruvate ratio: Suggests mitochondrial dysfunction.
• Elevated creatine kinase: Indicative of myopathy.
• Urine organic acids: May show elevated Krebs cycle intermediates.

Neuroimaging

• Brain MRI: stroke-like lesions not confined to vascular territories, often in the parietal-occipital regions. Signal abnormalities on T2/FLAIR imaging. Progressive cortical and subcortical atrophy. basal-ganglia calcifications may be present .
• MR spectroscopy: Elevated lactate peak; reduced N-acetylaspartate (NAA).
• CT: May show basal-ganglia calcifications.

Genetic Testing

• Blood leukocyte DNA: Initial testing for m.3243A>G in MT-TL1 (mitochondrial tRNA^Leu); sensitivity is approximately 80% but may underestimate mutant load due to selection against mutant mtDNA (see mitochondrial-dynamics) in blood .
• Urine sediment DNA: More reliable for detecting the m.3243A>G mutation due to higher heteroplasmy levels in urinary epithelial cells.
• Muscle biopsy DNA: Gold standard for quantifying heteroplasmy. Also reveals ragged-red fibers (modified Gomori trichrome) and COX-negative/SDH-positive fibers.

Treatment and Management

There is currently no curative therapy for MELAS. Management is multidisciplinary and focuses on symptom mitigation, prevention of metabolic crises, and slowing disease progression.

Acute Management of stroke-like episodes (see stroke

• L-Arginine: Intravenous L-arginine (0.5 g/kg) during acute stroke-like episodes (see stroke improves symptoms by enhancing NO synthesis and vasodilation. Oral arginine (0.15–0.3 g/kg/day) is used for prophylaxis .
• L-Citrulline: An alternative NO precursor with better oral bioavailability, showing promising results in clinical studies.
• Seizure management: Anti-seizure medications (levetiracetam, lacosamide preferred; valproic acid is contraindicated as it inhibits mitochondrial function).
• Supportive care: Hydration, electrolyte correction, avoidance of metabolic stressors.

Chronic Management

• Coenzyme Q10 (CoQ10): Supplementation (200–400 mg/day) to support electron transport chain function and provide antioxidant protection.
• High-dose taurine: Oral taurine (9–12 g/day) has shown efficacy in preventing stroke-like episodes (see stroke in a randomized controlled trial, possibly by improving mitochondrial tRNA modification .
• B-vitamin supplementation: Riboflavin (vitamin B2) as a cofactor for Complex I (see mitochondrial-dysfunction-ad) and II; thiamine for pyruvate dehydrogenase support.
• L-Carnitine: To support fatty acid metabolism and buffer toxic acyl-CoA species.
• Exercise therapy: Moderate aerobic exercise to stimulate mitochondrial biogenesis.
• Dietary management: Avoidance of fasting; some patients benefit from a high-fat, low-carbohydrate diet.

Emerging Therapies

• mitochondrial replacement therapy (MRT): Techniques such as pronuclear transfer and maternal spindle transfer to prevent maternal transmission of mtDNA (see mitochondrial-dynamics) mutations .
• Gene therapy: Approaches under investigation include allotopic expression of mitochondrial genes and mitochondrial-targeted nucleases to selectively eliminate mutant mtDNA (see mitochondrial-dynamics).
• mitochondrial transplantation: Experimental approaches to introduce healthy mitochondria into affected tissues.
• Elamipretide (SS-31): A mitochondrial-targeted peptide that stabilizes cardiolipin and improves respiratory chain function, under investigation in clinical trials.

Prognosis

MELAS carries a significant disease burden with progressive neurological decline:

• stroke-like episodes (see stroke tend to recur and accumulate, leading to progressive hemiparesis, cortical blindness, and cognitive deterioration.
• Life expectancy varies widely but is significantly reduced. Many patients die in childhood or young adulthood, though some with lower heteroplasmy levels survive into their 40s–60s.
• Causes of death include status epilepticus, respiratory failure, cardiac complications, and severe metabolic crises.
• The m.3243A>G mutation is associated with a spectrum of phenotypes beyond MELAS, including maternally inherited diabetes and deafness (MIDD) and chronic progressive external ophthalmoplegia (CPEO), depending on heteroplasmy levels and tissue distribution.

MELAS syndrome shares features with other mitochondrial disorders. See also:

• [merrf — Another common mitochondrial syndrome featuring myoclonus, seizures, and ragged-red fibers](/genes/th)
• [polg-related-mitochondrial-disorders — Including Alpers-Huttenlocher syndrome](/genes/polg)
• [friedreich-ataxia — A frataxin-related mitochondrial disorder](/genes/rel)
• [[Kearns-Sayre Syndrome — Mitochondrial deletion syndrome with external ophthalmoplegia](/genes/ar)
• [All Diseases

Background

The study of Melas Syndrome (mitochondrial Encephalomyopathy, lactic acidosis (see insulin-resistance-ad), And stroke Like Episodes) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Dysregulated iron homeostasis Drives mitochondrial Injury and ferroptosis susceptibility in MELAS fibroblasts.](https://pubmed.ncbi.nlm.nih.gov/41687756/) (2026 May) - Mitochondrion
• [MELAS syndrome complicated by anti-GFAP autoantibody positivity: a case report and literature review.](https://pubmed.ncbi.nlm.nih.gov/41794663/) (2026 Mar 7) - BMC neurology
• [Biomarking MELAS with neurofilament light chain and circulating cell free mitochondrial DNA.](https://pubmed.ncbi.nlm.nih.gov/41637969/) (2026 Mar) - Molecular genetics and metabolism
• [EEG, clinical, and MRI features of status epilepticus associated with mitochondrial diseases.](https://pubmed.ncbi.nlm.nih.gov/41729327/) (2026 Feb 23) - Journal of neurology
• [A novel tRNASer(AGY) 12244G > a variant impairs mitochondrial function and presents with classical MELAS phenotype.](https://pubmed.ncbi.nlm.nih.gov/41692888/) (2026 Feb 16) - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Pathway Diagram

References

• [MERRF - Myo- KSS - Kearns-Say- Leigh Syndrome - Subacute necrotizing encephalomyelopathy
• MERRF - Related mitochondria
• MT-TL1 - Most common MELAS mutation site
• MT-ND5 - Seco- FXN - Friedreich's ataxia gene (iron-sulfur cluster)
• POLG - Mitochondrial DNA polymerase

Pathophysiology

• [Mito- Mitochondrial Angiopathy - Vascular involvement
• Metabolic Encephalopathy - Energy failure mechanisms
• Lactic Acidosis - Metabolic hallmark
• Stroke-like Episodes - Unique MELAS feature

Treatment Approaches

• CoQ10 - Mitochondrial support
• L-Arginine - Vascular function
• Idebenone - Antioxidant therapy
• [Mitochondrial Cocktail](/therapeutics/mitochondrial cocktail) - Combination therapy